SECOND-LINE TREATMENTS IN PATIENTS WITH METASTATIC COLORECTAL CANCER PROGRESSED AFTER FIRST-LINE FOLFOXIRI

被引：0

作者：

Fornaro, Lorenzo ^{[1
]}

Vasile, Enrico ^{[1
]}

Masi, Gianluca ^{[1
]}

Loupakis, Fotios ^{[1
]}

Salvatore, Lisa ^{[1
]}

Stasi, Irene ^{[1
]}

Baldi, Giacomo Giulio ^{[1
]}

Cupini, Samanta ^{[1
]}

Barbara, Cecilia ^{[1
]}

Pfanner, Elisabetta ^{[2
]}

Brunetti, Isa Maura ^{[2
]}

Di Donato, Samantha ^{[2
]}

Caponi, Sara ^{[1
]}

Allegrini, Giacomo ^{[3
]}

Antonuzzo, Andrea ^{[1
]}

Ricci, Sergio ^{[2
]}

Chiara, Silvana ^{[4
]}

Vitello, Stefano ^{[5
]}

Andreuccetti, Michele ^{[1
]}

Falcone, Alfredo ^{[1
,6
]}

机构：

[1] Azienda Osped Univ Pisana, Dipartimento Int Oncol Med, Azienda USL Livorno 6, Ist Toscano Tumori, Pisa, Italy

[2] Univ Pisana, Azienda Osped, UO Oncol Med 1, Ist Toscano Tumori, Pisa, Italy

[3] Azienda USL 5, UO Oncol Med, Pontedera, PI, Italy

[4] Ist Nazl Tumori, UO Oncol Med, Genoa, Italy

[5] Azienda Osped St Elia, UO Oncol Med, Caltanissetta, Italy

[6] Univ Pisa, Dipartimento Oncol Trapianti & Nuove Tecnol Med, I-56100 Pisa, Italy

来源：

ANNALS OF ONCOLOGY | 2009年 / 20卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页数：1

共 50 条

[21] Secondary treatment and predictive factors for second-line chemotherapy after first-line oxaliplatin-based therapy in metastatic colorectal cancer
Sorbye, Halfdan
Berglund, Ake
Tveit, Kjell Magne
Ogreid, Dagfinn
Wanderas, Eva Hoff
Wentzel-Larsen, Tore
Dahl, Olav
Glimelius, Bengt
ACTA ONCOLOGICA, 2007, 46 (07) : 982 - 988
[22] FOLFOXIRI-Bev as first-line treatment in patients with metastatic colorectal cancer: a systematic review of RCT
Luih, B. Stephanie
Samudra, E.
Suwongto, G. Sonia
Glory, H.
Colfoort, K.
Wirajaya, P.
Kurniawan, A.
ANNALS OF ONCOLOGY, 2024, 35 : S1349 - S1350
[23] Phase Ib study of FOLFOXIRI plus ramucirumab as first-line treatment for patients with metastatic colorectal cancer
Kito, Yosuke
Satake, Hironaga
Taniguchi, Hiroya
Yamada, Takeshi
Horie, Yoshiki
Esaki, Taito
Denda, Tadamichi
Yasui, Hisateru
Izawa, Naoki
Masuishi, Toshiki
Moriwaki, Toshikazu
Mori, Keita
Yamazaki, Kentaro
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2020, 86 (02) : 277 - 284
[24] Phase Ib study of FOLFOXIRI plus ramucirumab as first-line treatment for patients with metastatic colorectal cancer
Yosuke Kito
Hironaga Satake
Hiroya Taniguchi
Takeshi Yamada
Yoshiki Horie
Taito Esaki
Tadamichi Denda
Hisateru Yasui
Naoki Izawa
Toshiki Masuishi
Toshikazu Moriwaki
Keita Mori
Kentaro Yamazaki
Cancer Chemotherapy and Pharmacology, 2020, 86 : 277 - 284
[25] Second-line therapy for metastatic colorectal cancer
Price, Timothy J.
LANCET ONCOLOGY, 2015, 16 (05): : 476 - 477
[26] Second-line management of metastatic colorectal cancer
Gallagher, David J.
Kemeny, Nancy
CLINICAL COLORECTAL CANCER, 2008, 7 (01) : 25 - 32
[27] Metastatic colorectal cancer:: First- and second-line treatment in 2005
Rougier, P
Lepère, C
SEMINARS IN ONCOLOGY, 2005, 32 (06) : S15 - S20
[28] Second line chemotherapy after first line irinotecan, oxaliplatin and 5-FU/LV (FOLFOXIRI) in metastatic colorectal cancer (MCRC) patients (pts).
Masi, G
Allegrini, G
Marcucci, L
Cupini, S
Brunetti, I
Fontana, E
Ricci, S
Cerri, E
Barbara, C
Falcone, A
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 291S - 291S
[29] Selection of Second-line Anti-angiogenic Agents After Failure of Bevacizumab-containing First-line Chemotherapy in Metastatic Colorectal Cancer
Boku, Narikazu
Yamamoto, Shun
CLINICAL COLORECTAL CANCER, 2018, 17 (04) : 251 - 254
[30] Clinical benefits of stabilization after second-line chemotherapy in patients with metastatic colorectal cancer
Henry-Launois, B
Becouarn, Y
Aussage, P
BULLETIN DU CANCER, 1999, 86 (02) : 195 - 201

← 1 2 3 4 5 →